微芯生物(688321)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688321 微芯生物

已收盘 08-14 15:00:00

{"stockData":{"symbol":"688321","market":"SH","secType":"STK","nameCN":"微芯生物","latestPrice":40.94,"timestamp":1755154800000,"preClose":41.18,"halted":0,"volume":21624518,"delay":0,"changeRate":-0.0058,"floatShares":408000000,"shares":408000000,"eps":-0.2831,"marketStatus":"已收盘","change":-0.24,"latestTime":"08-14 15:00:00","open":42,"high":42.95,"low":40.88,"amount":898000000,"amplitude":0.0503,"askPrice":40.96,"askSize":81,"bidPrice":40.94,"bidSize":145,"shortable":0,"etf":0,"ttmEps":-0.2831,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1755221400000},"marketStatusCode":5,"adr":0,"adjPreClose":41.18,"symbolType":"stock_kcb","openAndCloseTimeList":[[1755135000000,1755142200000],[1755147600000,1755154800000]],"highLimit":45.3,"lowLimit":37.06,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":407796477,"isCdr":false,"pbRate":11.61,"roa":"--","roe":"--","epsLYR":-0.2808,"committee":0.214153,"marketValue":16695000000,"turnoverRate":0.053,"status":1,"afterMarket":{"amount":0,"volume":0,"close":40.94,"buyVolume":0,"sellVolume":0,"time":1755156839260,"indexStatus":"已收盘 08-14 15:30:00","preClose":41.18},"floatMarketCap":16695000000},"requestUrl":"/m/hq/s/688321","defaultTab":"news","newsList":[{"id":"2559670423","title":"8月13日微芯生物涨14.39%，民生加银精选混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2559670423","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559670423?lang=zh_cn&edition=full","pubTime":"2025-08-13 16:19","pubTimestamp":1755073195,"startTime":"0","endTime":"0","summary":"证券之星消息，8月13日微芯生物涨14.39%创60日新高，收盘报41.18元，换手率9.05%，成交量36.91万手，成交额14.42亿元。刘霄汉在任的基金产品包括:民生加银品质消费股票A，管理时间为2021年8月13日至今，期间收益率为-40.42%；民生加银创新成长混合A，管理时间为2024年8月28日至今，期间收益率为48.58%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081300025605.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321"],"gpt_icon":0},{"id":"2558665370","title":"8月11日微芯生物现3笔折价17.19%的大宗交易 合计成交793.86万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2558665370","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558665370?lang=zh_cn&edition=full","pubTime":"2025-08-11 17:22","pubTimestamp":1754904161,"startTime":"0","endTime":"0","summary":"证券之星消息，8月11日微芯生物发生大宗交易，交易数据如下：近三个月该股共发生41笔大宗交易，合计成交6.68万手，折价成交41笔。该股近期无解禁股上市。截至2025年8月11日收盘，微芯生物(688321)报收于36.59元，上涨5.14%，换手率3.62%，成交量14.76万手，成交额5.29亿元。该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081100028268.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2558639443","title":"微芯生物涨5.23% 政策利好与资金博弈共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2558639443","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558639443?lang=zh_cn&edition=full","pubTime":"2025-08-11 13:40","pubTimestamp":1754890855,"startTime":"0","endTime":"0","summary":"微芯生物股价今日大幅上涨，截至13点40分，最新价报36.62元/股，涨幅达5.23%。资金博弈与政策兑现共振微芯生物近期股价波动与资金面剧烈博弈密切相关。截至8月4日，主力资金5日累计净流出1.97亿元，净流入折价现象频现，7月25日3325万元交易以11.08%折价成交，显示部分资金兑现意愿强烈。叠加医药板块轮动加速，市场对政策利好兑现节奏分歧加大。2025年前三季度营收同比增长24.24%至1.62亿元，动态市盈率-129.38倍显示盈利拐点尚未到来。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811134102a6def3f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811134102a6def3f1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2558363941","title":"猴痘概念盘中拉升，亚太药业涨5.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558363941","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558363941?lang=zh_cn&edition=full","pubTime":"2025-08-11 13:38","pubTimestamp":1754890730,"startTime":"0","endTime":"0","summary":"08月11日，猴痘概念盘中拉升，截至13点38分，猴痘概念整体指数上涨1.00%，报1154.920点。从个股上来看，该概念的成分股中，亚太药业涨5.72%，翰宇药业、微芯生物、阿拉丁涨幅居前。从资金上来看，截止发稿，猴痘概念主力净流入为-1.02亿，其中亚太药业受到资金热捧，主力净流入7845.42万；拉长时间线来看，该板块近20日主力资金净流入-48.05亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081113385094dc1845&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081113385094dc1845&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["002370","BK0132","688321","BK0239"],"gpt_icon":0},{"id":"2558338446","title":"非酒精性脂肪性肝炎(NASH)概念盘中拉升，福瑞股份涨2.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558338446","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558338446?lang=zh_cn&edition=full","pubTime":"2025-08-11 10:05","pubTimestamp":1754877935,"startTime":"0","endTime":"0","summary":"08月11日，非酒精性脂肪性肝炎(NASH)概念盘中拉升，截至10点05分，非酒精性脂肪性肝炎(NASH)概念整体指数上涨1.02%，报1386.250点。从个股上来看，该概念的成分股中，福瑞股份涨2.47%，众生药业、ST诺泰、微芯生物涨幅居前。从资金上来看，截止发稿，非酒精性脂肪性肝炎(NASH)概念主力净流入为7459.31万，其中迈瑞医疗受到资金热捧，主力净流入3273.96万；拉长时间线来看，该板块近20日主力资金净流入6.29亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811100535a6de9e19&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811100535a6de9e19&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0028","BK0096","688321","300049","BK0146","688076","BK0114","BK0251","BK0113","BK0239"],"gpt_icon":0},{"id":"2557551320","title":"非酒精性脂肪性肝炎(NASH)概念盘中跳水，福瑞股份跌1.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557551320","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557551320?lang=zh_cn&edition=full","pubTime":"2025-08-08 09:38","pubTimestamp":1754617111,"startTime":"0","endTime":"0","summary":"08月08日，非酒精性脂肪性肝炎(NASH)概念盘中跳水，截至09点38分，非酒精性脂肪性肝炎(NASH)概念整体指数下跌0.54%，报1363.600点。从个股上来看，该概念的成分股中，福瑞股份跌1.51%，微芯生物、康弘药业、华东医药跌幅居前。从资金上来看，截止发稿，非酒精性脂肪性肝炎(NASH)概念主力净流入为2982.23万，其中众生药业受到资金热捧，主力净流入2782.02万；拉长时间线来看，该板块近20日主力资金净流入3.38亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808093831a6d9d732&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808093831a6d9d732&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0146","BK0251","BK0239","688321","BK0113","BK0114","BK0096","BK0028","300049"],"gpt_icon":0},{"id":"2557584231","title":"非酒精性脂肪性肝炎(NASH)概念盘中拉升，福瑞股份涨3.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557584231","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557584231?lang=zh_cn&edition=full","pubTime":"2025-08-07 09:35","pubTimestamp":1754530540,"startTime":"0","endTime":"0","summary":"08月07日，非酒精性脂肪性肝炎(NASH)概念盘中拉升，截至09点35分，非酒精性脂肪性肝炎(NASH)概念整体指数上涨0.51%，报1390.160点。从个股上来看，该概念的成分股中，福瑞股份涨3.30%，微芯生物、ST诺泰、众生药业涨幅居前。从资金上来看，截止发稿，非酒精性脂肪性肝炎(NASH)概念主力净流入为-1950.36万，其中ST诺泰受到资金热捧，主力净流入460.96万；拉长时间线来看，该板块近20日主力资金净流入2.81亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080709354094d488f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080709354094d488f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0028","688321","BK0114","300049","BK0251","BK0096","688076","BK0113","BK0146","BK0239"],"gpt_icon":0},{"id":"2557322646","title":"8月6日微芯生物现1笔折价15.77%的大宗交易 合计成交202.36万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557322646","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557322646?lang=zh_cn&edition=full","pubTime":"2025-08-06 17:20","pubTimestamp":1754472054,"startTime":"0","endTime":"0","summary":"证券之星消息，8月6日微芯生物发生大宗交易，交易数据如下：大宗交易成交价格30.66元，相对当日收盘价折价15.77%，成交6.6万股，成交金额202.36万元，买方营业部为机构专用，卖方营业部为国投证券股份有限公司深圳宝安海秀路证券营业部。近三个月该股共发生38笔大宗交易，合计成交6.41万手，折价成交38笔。截至2025年8月6日收盘，微芯生物报收于36.4元，下跌1.46%，换手率4.08%，成交量16.63万手，成交额6.09亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080600028110.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2557364977","title":"8月5日微芯生物现1笔折价18.38%的大宗交易 合计成交211.05万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557364977","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557364977?lang=zh_cn&edition=full","pubTime":"2025-08-05 17:20","pubTimestamp":1754385627,"startTime":"0","endTime":"0","summary":"证券之星消息，8月5日微芯生物发生大宗交易，交易数据如下：大宗交易成交价格30.15元，相对当日收盘价折价18.38%，成交7万股，成交金额211.05万元，买方营业部为机构专用，卖方营业部为国投证券股份有限公司深圳宝安海秀路证券营业部。近三个月该股共发生37笔大宗交易，合计成交6.35万手，折价成交37笔。截至2025年8月5日收盘，微芯生物报收于36.94元，上涨1.68%，换手率3.27%，成交量13.32万手，成交额4.9亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080500029268.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321"],"gpt_icon":0},{"id":"2557350046","title":"非酒精性脂肪性肝炎(NASH)概念盘中拉升，华东医药涨3.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557350046","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557350046?lang=zh_cn&edition=full","pubTime":"2025-08-05 14:36","pubTimestamp":1754375774,"startTime":"0","endTime":"0","summary":"08月05日，非酒精性脂肪性肝炎(NASH)概念盘中拉升，截至14点36分，非酒精性脂肪性肝炎(NASH)概念整体指数上涨1.00%，报1384.490点。从个股上来看，该概念的成分股中，华东医药涨3.54%，ST诺泰、康弘药业、微芯生物涨幅居前。从资金上来看，截止发稿，非酒精性脂肪性肝炎(NASH)概念主力净流入为-580.72万，其中通化东宝受到资金热捧，主力净流入4524.58万；拉长时间线来看，该板块近20日主力资金净流入2.97亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080514361494d098d1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080514361494d098d1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688076","LU2328871848.SGD","BK0188","BK0239","688321","BK0209","000963","BK0196","LU1969619763.USD","BK0132","BK0183","BK0187","BK0175"],"gpt_icon":0},{"id":"2556871752","title":"微芯生物股价下跌5.02% 政策利好兑现资金抛售致股价回撤","url":"https://stock-news.laohu8.com/highlight/detail?id=2556871752","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556871752?lang=zh_cn&edition=full","pubTime":"2025-08-04 09:50","pubTimestamp":1754272245,"startTime":"0","endTime":"0","summary":"微芯生物股价大幅下跌，最新价35.57元/股，跌幅5.02%。政策驱动与资金面共振微芯生物近期净流入与政策预期及资金博弈密切相关。7月创新药支持政策落地后，主力资金单日净流入超9800万元，推动股价单日涨幅达11.44%，但次日沪股通与机构资金迅速抛售3.55亿元，导致股价回撤超8%，显示政策利好兑现后资金获利了结特征。此外，净流入折价频现，7月25日以11.08%折价成交的3325万元大宗交易，叠加近3个月累计18笔大宗交易，进一步加剧市场分歧。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804095050a6d13abc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804095050a6d13abc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2556894847","title":"微芯生物：CS231295片治疗晚期实体瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2556894847","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556894847?lang=zh_cn&edition=full","pubTime":"2025-08-01 18:09","pubTimestamp":1754042957,"startTime":"0","endTime":"0","summary":"投资者提问：您好，CS231295片主要针对什么肿瘤有效果？比如肺癌、肝癌等，还是CS231295只要是实体肿瘤就有可能效果？公司自主研发的透脑AuroraB选择性抑制剂CS231295正在中国以及美国开展治疗晚期实体瘤的临床试验。CS231295作为透脑AuroraB选择性抑制剂，一方面通过精准抑制肿瘤特异性过表达的AuroraB激酶，诱导合成致死效应，直击RB1缺失等难治性肿瘤的基因脆弱性；另一方面，凭借良好的血脑屏障穿透能力，对脑部原发或脑转移性肿瘤存在明显的治疗优势。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080100033205.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2556868837","title":"微芯生物涨5.13% 政策催化与资金流入共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2556868837","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556868837?lang=zh_cn&edition=full","pubTime":"2025-08-01 09:56","pubTimestamp":1754013395,"startTime":"0","endTime":"0","summary":"微芯生物股价今日大幅上涨，最新价报39.16元，上涨5.13%。政策驱动与资金博弈共振微芯生物近期股价波动主要受政策催化与资金面扰动影响。截至7月28日，主力资金连续5个交易日累计净流出1.97亿元，反映医药板块轮动加速下，短线资金博弈加剧股价波动。产品梯队与估值重构博弈微芯生物长期估值锚定于核心产品的商业化进程。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250801095639a6ccb3b9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250801095639a6ccb3b9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2556852097","title":"微芯生物透脑Aurora B选择性抑制剂美国IND获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2556852097","media":"医药魔方","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556852097?lang=zh_cn&edition=full","pubTime":"2025-08-01 07:55","pubTimestamp":1754006134,"startTime":"0","endTime":"0","summary":"深圳微芯生物科技股份有限公司宣布，其全资子公司微芯生物科技（美国）有限公司申报的新一代透脑Aurora B选择性抑制剂CS231295片用于治疗晚期实体瘤的临床试验申请已获批准。CS231295是微芯生物基于在相关作用机制领域多年探索发现的新一代透脑Aurora B选择性抑制剂。CS231295凭借独特的机制与化学结构，具有与化疗、靶向及肿瘤免疫等多种药物协同的治疗效应。CS231295已于2025年5月在中国完成首次人体I期临床试验首例患者入组。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250801084253a6cc8cc2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250801084253a6cc8cc2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2555008740","title":"微芯生物：CS231295片临床试验申请获得FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2555008740","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555008740?lang=zh_cn&edition=full","pubTime":"2025-07-31 16:48","pubTimestamp":1753951738,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["688321","03347","BK1141","BK1576","BK0239","BK1583"],"gpt_icon":0},{"id":"2555802000","title":"微芯生物(688321.SH)：CS231295临床试验申请获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2555802000","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555802000?lang=zh_cn&edition=full","pubTime":"2025-07-31 16:48","pubTimestamp":1753951709,"startTime":"0","endTime":"0","summary":"智通财经APP讯，微芯生物 公告，的全资子公司微芯生物科技(美国)有限公司于7月31日收到美国食品药品监督管理局签发的关于允许公司自主研发的CS231295开展治疗晚期实体瘤的I期临床试验的通知。公告显示，CS231295作为透脑AuroraB选择性抑制剂，一方面通过精准抑制肿瘤特异性过表达的AuroraB激酶，诱导合成致死效应，直击RB1基因脆弱性;另一方面，凭借良好的血脑屏障穿透能力，对脑部原发或脑转移性肿瘤存在明显的治疗优势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1324168.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","BK1576","688321","BK0239","BK1583","BK1141"],"gpt_icon":0},{"id":"2555431026","title":"微芯生物7月30日现1笔大宗交易 总成交金额800.04万元 其中机构买入800.04万元 溢价率为-17.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555431026","media":"新浪证券-红岸工作室","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555431026?lang=zh_cn&edition=full","pubTime":"2025-07-30 17:40","pubTimestamp":1753868400,"startTime":"0","endTime":"0","summary":"　　7月30日，微芯生物收跌3.18%，收盘价为37.15元，发生1笔大宗交易，合计成交量26.06万股，成交金额800.04万元。　　第1笔成交价格为30.70元，成交26.06万股，成交金额800.04万元，溢价率为-17.36%，买方营业部为机构专用，卖方营业部为国投证券股份有限公司深圳宝安海秀路证券营业部。　　进一步统计，近3个月内该股累计发生35笔大宗交易，合计成交金额为1.88亿元。该股近5个交易日累计上涨6.05%，主力资金合计净流出1.55亿元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2025-07-30/doc-infifzss8278506.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2555867014","title":"非酒精性脂肪性肝炎(NASH)概念盘中跳水，微芯生物跌4.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555867014","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555867014?lang=zh_cn&edition=full","pubTime":"2025-07-30 13:51","pubTimestamp":1753854712,"startTime":"0","endTime":"0","summary":"07月30日，非酒精性脂肪性肝炎(NASH)概念盘中跳水，截至13点51分，非酒精性脂肪性肝炎(NASH)概念整体指数下跌1.05%，报1363.890点。从个股上来看，该概念的成分股中，微芯生物跌4.12%，福瑞股份、康弘药业、众生药业跌幅居前。从资金上来看，截止发稿，非酒精性脂肪性肝炎(NASH)概念主力净流入为-1.95亿，其中迈瑞医疗受到资金热捧，主力净流入7474.62万；拉长时间线来看，该板块近20日主力资金净流入-4.81亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073013515294c328e9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073013515294c328e9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2555009373","title":"非酒精性脂肪性肝炎(NASH)概念盘中跳水，福瑞股份跌2.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555009373","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555009373?lang=zh_cn&edition=full","pubTime":"2025-07-30 09:52","pubTimestamp":1753840377,"startTime":"0","endTime":"0","summary":"07月30日，非酒精性脂肪性肝炎(NASH)概念盘中跳水，截至09点52分，非酒精性脂肪性肝炎(NASH)概念整体指数下跌0.50%，报1376.980点。从个股上来看，该概念的成分股中，福瑞股份跌2.76%，微芯生物、ST诺泰、华东医药跌幅居前。从资金上来看，截止发稿，非酒精性脂肪性肝炎(NASH)概念主力净流入为-4587.24万，其中迈瑞医疗受到资金热捧，主力净流入7240.13万；拉长时间线来看，该板块近20日主力资金净流入-4.81亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730095257a6c8b653&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730095257a6c8b653&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","BK0028","BK0239","688321","BK0146","BK0096","BK0113","688076","BK0114","300049"],"gpt_icon":0},{"id":"2555031502","title":"7月29日微芯生物现16笔折价20.25%的大宗交易 合计成交5812.16万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555031502","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555031502?lang=zh_cn&edition=full","pubTime":"2025-07-29 17:21","pubTimestamp":1753780867,"startTime":"0","endTime":"0","summary":"证券之星消息，7月29日微芯生物发生大宗交易，交易数据如下：近三个月该股共发生34笔大宗交易，合计成交5.87万手，折价成交34笔。该股近期无解禁股上市。截至2025年7月29日收盘，微芯生物(688321)报收于38.37元，上涨12.85%，换手率9.85%，成交量40.18万手，成交额14.9亿元。该股最近90天内共有2家机构给出评级，买入评级1家，增持评级1家。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072900028804.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1755212024100,"stockEarnings":[{"period":"1week","weight":0.1436},{"period":"1month","weight":0.1445},{"period":"3month","weight":1.3448},{"period":"6month","weight":1.225},{"period":"1year","weight":1.3434},{"period":"ytd","weight":1.2034}],"compareEarnings":[{"period":"1week","weight":0.0074},{"period":"1month","weight":0.0461},{"period":"3month","weight":0.0888},{"period":"6month","weight":0.0955},{"period":"1year","weight":0.2862},{"period":"ytd","weight":0.0939}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳微芯生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"17684人(较上一季度减少1.85%)","perCapita":"23060股","listingDate":"2019-08-12","address":"广东省深圳市南山区西丽街道曙光社区智谷产业园B栋21F-24F","registeredCapital":"40779万元","survey":"　　深圳微芯生物科技股份有限公司的主营业务是药物技术开发、相关成果商业应用。公司的主要产品是爱谱沙（西达本胺）、双洛平（西格列他钠）、西奥罗尼、其他在研产品。","listedPrice":20.43},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.7","shortVersion":"4.34.7","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"微芯生物(688321)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供微芯生物(688321)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"微芯生物,688321,微芯生物股票,微芯生物股票老虎,微芯生物股票老虎国际,微芯生物行情,微芯生物股票行情,微芯生物股价,微芯生物股市,微芯生物股票价格,微芯生物股票交易,微芯生物股票购买,微芯生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"微芯生物(688321)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供微芯生物(688321)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}